737 related articles for article (PubMed ID: 9830622)
1. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
Benson AB
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622
[TBL] [Abstract][Full Text] [Related]
2. Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer.
Grem JL
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):13-9. PubMed ID: 11219972
[TBL] [Abstract][Full Text] [Related]
3. Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
Link KH; Kornmann M; Leder G; Pillasch AF; Sunelaitis E; Schatz M; Pressmar J; Beger HG
Gan To Kagaku Ryoho; 1999 Feb; 26(3):269-81. PubMed ID: 10065089
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Arkenau HT; Arnold D; Cassidy J; Diaz-Rubio E; Douillard JY; Hochster H; Martoni A; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; Porschen R
J Clin Oncol; 2008 Dec; 26(36):5910-7. PubMed ID: 19018087
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
[TBL] [Abstract][Full Text] [Related]
6. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.
Ducreux M; Ychou M; Laplanche A; Gamelin E; Lasser P; Husseini F; Quenet F; Viret F; Jacob JH; Boige V; Elias D; Delperro JR; Luboinski M;
J Clin Oncol; 2005 Aug; 23(22):4881-7. PubMed ID: 16009952
[TBL] [Abstract][Full Text] [Related]
7. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
[TBL] [Abstract][Full Text] [Related]
8. Therapy for advanced colorectal cancer.
Benson AB
Semin Oncol; 1998 Oct; 25(5 Suppl 11):2-11. PubMed ID: 9786311
[TBL] [Abstract][Full Text] [Related]
9. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
[TBL] [Abstract][Full Text] [Related]
10. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
Patt YZ; Hoque A; Lozano R; Pozdur R; Chase J; Carrasco H; Chuang V; Delpassand ES; Ellis L; Curley S; Roh M; Jones DV
J Clin Oncol; 1997 Apr; 15(4):1432-8. PubMed ID: 9193336
[TBL] [Abstract][Full Text] [Related]
12. Biomodulation of Fluorouracil in colorectal cancer.
Ardalan B; Luis R; Jaime M; Franceschi D
Cancer Invest; 1998; 16(4):237-51. PubMed ID: 9589033
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
de Gramont A; Bosset JF; Milan C; Rougier P; Bouché O; Etienne PL; Morvan F; Louvet C; Guillot T; François E; Bedenne L
J Clin Oncol; 1997 Feb; 15(2):808-15. PubMed ID: 9053508
[TBL] [Abstract][Full Text] [Related]
14. Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer?
Goldberg RM
Semin Oncol; 1998 Oct; 25(5 Suppl 11):21-8. PubMed ID: 9786313
[TBL] [Abstract][Full Text] [Related]
15. Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer.
Nobile MT; Barzacch MC; Sanguineti O; Chiara S; Gozza A; Vincenti M; Lavarello A; Cognein P; Lionetto R; Percivale PL; Bertoglio S; Murolo C; Esposito M; Vannozzi MO; Rosso R
Anticancer Res; 1998; 18(1B):517-21. PubMed ID: 9568171
[TBL] [Abstract][Full Text] [Related]
16. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
[TBL] [Abstract][Full Text] [Related]
17. Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Bin Q; Li J; Liao C; Cao Y; Gao F
Colorectal Dis; 2011 Aug; 13(8):837-45. PubMed ID: 20050863
[TBL] [Abstract][Full Text] [Related]
18. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
Klaassen U; Wilke H; Seeber S
J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
[TBL] [Abstract][Full Text] [Related]
19. Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
Sobrero A; Zaniboni A; Frassineti GL; Aschele C; Guglielmi A; Giuliani R; Ravaioli A; Lanfranco C; Caroti C; Arnoldi E; Barni S; Gallo L; Pessi MA; Turci D; Cortesi E; Grossi F; Frontini L; Piazza E; Bruzzi P; Labianca R
Ann Oncol; 2000 Nov; 11(11):1413-20. PubMed ID: 11142481
[TBL] [Abstract][Full Text] [Related]
20. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
